Monica Forbes
Corporate Officer/Principal bei APOGEE THERAPEUTICS, INC.
Vermögen: 57 392 $ am 31.03.2024
Profil
Monica Forbes is a Senior Vice President-Finance at Apogee Therapeutics, Inc. She was previously the Chief Financial Officer & Vice President at Orexigen Therapeutics, Inc. from 2014 to 2018, and at Nalpropion Pharmaceuticals, Inc. from 2018 to 2019.
From 2019 to present, she held the position of Chief Financial Officer & Vice President at Sesen Bio, Inc. Ms. Forbes completed her undergraduate degree at San Diego State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.03.2023 | 25 283 ( 0,06% ) | 57 392 $ | 31.03.2024 |
Aktive Positionen von Monica Forbes
| Unternehmen | Position | Beginn |
|---|---|---|
| APOGEE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.05.2023 |
Ehemalige bekannte Positionen von Monica Forbes
| Unternehmen | Position | Ende |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Director of Finance/CFO | 07.03.2023 |
Nalpropion Pharmaceuticals, Inc.
 Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ. | Director of Finance/CFO | 01.04.2019 |
| OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 27.07.2018 |
Ausbildung von Monica Forbes
| San Diego State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| APOGEE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Nalpropion Pharmaceuticals, Inc.
Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ. | Health Services |
